Joint Formulary & PAD

Cenobamate - Epilepsy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

For ADULTS, blue with specialist prescriber initation and supply for at least 12 weeks

Documents :
 
 

Status 2

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Off Label
SPC
Restrictions / Comments :
Important

Non-formulary for CHILDREN.

Licensed for use in adults only

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Cenobamate
Indication :
Epilepsy
Group Name :
Keywords :
Focal onset seizures
Brand Names Include :
Ontozry
Important Information :
Latest Additions Date From :
06 Aug 2025
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Cenobamate is used to treat.

  • No records returned.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a change in traffic light status for Cenobamate for treating focal onset seizures in epilepsy in Adults patients in line with the review of NICE TA753.

Cenobamate will be given a BLUE (with specialist prescriber initiation) with 12 weeks prescribing by the specialist team prior to transfer of care

The Surrey Heartlands Integrated Care System Area Prescribing Committee agrees that Cenobamate for treating focal onset seizures in epilepsy in children and young people under the age of 18 will be given a NON-FORMULARY traffic light status.